ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
ANI Pharma dropped an 8-K on Feb 5th - check it for financial updates.
AI Summary
On February 5, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing provides an update on ANI Pharmaceuticals' financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- ANI PHARMACEUTICALS INC (company) — Registrant
- February 5, 2025 (date) — Date of Report
- 210 Main Street West Baudette , Minnesota 56623 (address) — Principal executive offices
- BIOSANTE PHARMACEUTICALS INC (company) — Former company name
- BEN ABRAHAM TECHNOLOGIES INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by ANI Pharmaceuticals?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on February 5, 2025.
What is ANI Pharmaceuticals' principal executive office address?
ANI Pharmaceuticals' principal executive office is located at 210 Main Street West, Baudette, Minnesota 56623.
Has ANI Pharmaceuticals changed its name previously?
Yes, ANI Pharmaceuticals was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.
What is the Commission File Number for ANI Pharmaceuticals?
The Commission File Number for ANI Pharmaceuticals is 001-31812.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-02-05 07:00:31
Filing Documents
- ani-20250205.htm (8-K) — 29KB
- exhibit991investordeck20.htm (EX-99.1) — 46KB
- exhibit991investordeck20001.jpg (GRAPHIC) — 62KB
- exhibit991investordeck20002.jpg (GRAPHIC) — 225KB
- exhibit991investordeck20003.jpg (GRAPHIC) — 195KB
- exhibit991investordeck20004.jpg (GRAPHIC) — 136KB
- exhibit991investordeck20005.jpg (GRAPHIC) — 133KB
- exhibit991investordeck20006.jpg (GRAPHIC) — 134KB
- exhibit991investordeck20007.jpg (GRAPHIC) — 71KB
- exhibit991investordeck20008.jpg (GRAPHIC) — 70KB
- exhibit991investordeck20009.jpg (GRAPHIC) — 140KB
- exhibit991investordeck20010.jpg (GRAPHIC) — 108KB
- exhibit991investordeck20011.jpg (GRAPHIC) — 113KB
- exhibit991investordeck20012.jpg (GRAPHIC) — 114KB
- exhibit991investordeck20013.jpg (GRAPHIC) — 172KB
- exhibit991investordeck20014.jpg (GRAPHIC) — 164KB
- exhibit991investordeck20015.jpg (GRAPHIC) — 129KB
- exhibit991investordeck20016.jpg (GRAPHIC) — 96KB
- exhibit991investordeck20017.jpg (GRAPHIC) — 129KB
- exhibit991investordeck20018.jpg (GRAPHIC) — 124KB
- exhibit991investordeck20019.jpg (GRAPHIC) — 140KB
- exhibit991investordeck20020.jpg (GRAPHIC) — 135KB
- exhibit991investordeck20021.jpg (GRAPHIC) — 136KB
- exhibit991investordeck20022.jpg (GRAPHIC) — 166KB
- exhibit991investordeck20023.jpg (GRAPHIC) — 175KB
- exhibit991investordeck20024.jpg (GRAPHIC) — 56KB
- exhibit991investordeck20025.jpg (GRAPHIC) — 162KB
- exhibit991investordeck20026.jpg (GRAPHIC) — 143KB
- exhibit991investordeck20027.jpg (GRAPHIC) — 87KB
- exhibit991investordeck20028.jpg (GRAPHIC) — 56KB
- 0001023024-25-000006.txt ( ) — 5137KB
- ani-20250205.xsd (EX-101.SCH) — 2KB
- ani-20250205_lab.xml (EX-101.LAB) — 21KB
- ani-20250205_pre.xml (EX-101.PRE) — 12KB
- ani-20250205_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On February 5, 2025, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., and other members of the senior leadership team will present at the Guggenheim Biotech Conference in New York, New York. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
01
Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated February 5, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 5, 2025 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer